Neuroendocrine tumors are rare, accounting for less than 1% of all malignant tumors, and most of them occur in the stomach, intestines, and pancreas. The most common type of cancer in this type of tumor is carcinoid, with an incidence of about 2.5/100000, accounting for 50% of all gastrointestinal pancreatic neuroendocrine tumors. Carcinoid tumors can be divided into anterior intestine (lung, lung, Bronchus and upper gastrointestinal tract up to jejunum), midgut (ileum and appendix) and hindgut (rectum and rectum). Such tumors can occur in the entire neuroendocrine system, but the most common site of involvement is the pancreas. Neuroendocrine tumors can be divided into two major categories according to whether the substances secreted by the isisu cause typical clinical symptoms mdash; mdash; functional and non-functional.
Njengamanje, ukwelashwa okuphumelela kakhulu kwezicubu ze-neuroendocrine emhlabeni yi-peptide receptor radionuclide therapy (PRRT). Okulandelayo yindatshana ebhalwe ngudokotela waseMelika ekwelashweni kwe-peptide receptor radionuclide:
Yini i-peptide receptor Radionuclide therapy (PRRT)?
Yini i-peptide receptor radionuclide therapy (PRRT) futhi isebenza kanjani?
I-Peptide receptor radionuclide therapy (PRRT) iyindlela yokwelashwa ehlobene namangqamuzana (ebizwa nangokuthi i-radioisotope therapy) esetshenziselwa ukwelapha izinhlobo ezithile zomdlavuza, ezibizwa ngokuthi i-neuroendocrine malignancies noma izicubu ze-Neuroendocrine (izicubu ze-neuroendocrine). I-Peptide receptor radionuclide therapy (PRRT) nayo iyafundwa njengokwelashwa kwezicubu zomqolo nezindlala zepancreatic.
Ekwelashweni kwe-peptide receptor radionuclide ( PRRT), iphrotheni (noma i-peptide) ebizwa ngokuthi i-cell targeting ebizwa ngokuthi i-octreotide, ehlanganiswe nomthamo omncane wezinto ezikhipha imisebe, noma i-radionuclide, ikhiqiza uhlobo olukhethekile lwe-radiopharmaceutical olubizwa ngokuthi i-radioactive peptide. Lapho ijova egazini lesiguli, le radioactivity ingena futhi inamathele kumangqamuzana e-neuroendocrine tumor, inikeze i-radiotherapy enedosi ephezulu esilonda somdlavuza.
Emangqamuzaneni amaningi we-neuroendocrine tumor, ukucebisa (okubizwa ngokuthi yi-overexpression) kunenombolo enkulu yezinhlobo ezikhethekile ze-surface receptors-le protein isatshalaliswa engqamuzaneni leseli-i-hormone enamathele emzimbeni ibizwa ngokuthi yi-growth hormone inhibitory factor. I-Octreotide iyi-hormone eyenziwe elebhu, enamathiselwe kwi-neuroendocrine tumor growth hormone inhibitory factor receptor. Ku-peptide receptor radionuclide therapy (PRRT), i-octreotide ihlanganiswe nemithamo yokwelapha ye-radionuclide yttrium-90 (Y-90) ne-lutetium 177 (Lu-177) i-radionuclide esetshenziswa kakhulu.
Yiziphi izifo ezingelashwa yi-peptide receptor radionuclide therapy (PRRT)?
Is peptide receptor radionuclide therapy ( PRRT) used to treat neuroendocrine tumors? (NETs), including izicubu ze-carcinoid, pancreatic islet cell carcinoma, small cell lung cancer, pheochromocytoma (a rare tumor formed in the adrenal glands), stomach-intestine-pancreas (stomach, intestine and pancreas) neuroendocrine tumors, And rare thyroid cancer that does not respond to radioactive iodine therapy.
I-Peptide receptor radionuclide therapy (PRRT) inketho yeziguli:
• Isiguli sithuthukile futhi / noma sithuthukile izicubu ze-neuroendocrine
• Iziguli ezingakulungele ukuhlinzwa
• Izimpawu zesiguli aziphenduli kweminye imithi
Inhloso enkulu yokwelashwa kwe-peptide receptor radionuclide (PRRT) ukusiza ukukhulula izimpawu, ukumisa noma ukubambezela ukuqhubeka kwesimila nokwenza ngcono ukusinda okuphelele.
Ngabe isebenza kanjani i-peptide receptor radionuclide therapy (PRRT)?
Ngokuya ngohlobo lomdlavuza owelaswayo nemishini yokwelapha esebenzisa inqubo yokwelashwa, iziguli zingathola imijikelezo efinyelela kwayi-10 yePeptide receptor radionuclide therapy (PRRT), ehlukaniswe ezinyangeni ezi-2-3. Ngokuya ngosizo lwe-radionuclide ukwenziwa kanye nemithetho yendawo, le nqubo ingasetshenziswa njengenqubo yokwelashwa kweziguli, noma ingadinga izinsuku ezimbalwa zokwelashwa esibhedlela.
Yonke i-Peptide receptor radionuclide therapy (PRRT) iqala lapho ama-amino acid ejojowe kalula emthanjeni ukuvikela izinso zesiguli emisebeni. I-peptide enemisebe kamuva ifakwa esigulini, ilandelwe ngesisombululo esengeziwe se-amino acid. Sekukonke, isikhathi sokwelashwa sithathe cishe amahora angama-4.
Ngesikhathi sokwelashwa okulandelayo, kungenziwa ukuskena kwe-imaging imaging ukubheka ukuthi i-peptide enemisebe efakiwe ifakiwe emzimbeni, yize lokhu kungaphoqelekile.
Ziyini izinzuzo zepeptide receptor radionuclide therapy (PRRT)?
I-Peptide receptor radionuclide therapy ( PRRT) nezinye izindlela zokwelapha zamangqamuzana zinganikeza ukwelashwa komdlavuza komuntu ngamunye ngoba imithi ye-radiopharmaceuticals ingalungiswa ngokuya ngezici zebhayoloji eziyingqayizivele zesiguli kanye nezici zamangqamuzana zesimila. I-Peptide receptor radionuclide therapy (PRRT) nayo ithathwa njengokwelapha okuhlosiwe, ngoba ama-peptide anemisebe anamandla okubhubhisa ngokukhetha amaseli esimila se-neuroendocrine, kuyilapho ekhawulela ukuchayeka kwezicubu ezivamile emisebeni. Ngakho-ke, ngokuvamile, i-peptide receptor radionuclide therapy (PRRT) inemiphumela engemihle uma iqhathaniswa ne-chemotherapy.
I-Peptide receptor radionuclide therapy (PRRT) iyinhlobo enezinga eliphakeme lokusebenza ngempumelelo kwezinketho zokwelashwa zokulawulwa kwesimila se-neuroendocrine kokuthuthukile, okuqhubekayo. I-Peptide receptor radionuclide therapy (PRRT) akuyona indlela yokwelapha, kepha ikhonjisiwe ukuthi isiza ekunciphiseni izimpawu nokubambezela ukuqhubeka kwezifo.
Ngabe i-peptide receptor radionuclide therapy (PRRT) iphephile?
Konke ukwelashwa, kufaka phakathi i-peptide receptor radionuclide therapy (PRRT), kunemiphumela engemihle nezingozi. Kufanele uxoxe ngobungozi nezinzuzo ze-peptide receptor radionuclide therapy (PRRT) nomhlinzeki wakho wokwelashwa, kanye nokunye ukwelashwa okucabangayo. Ngokuya ngomlando wakho wezokwelapha, umhlinzeki wakho wezokwelapha uzokusiza ukuthi unqume ukuthi i-peptide receptor radionuclide therapy (PRRT) ukukhetha kwakho okulungile yini. Qiniseka ukuthi wazisa umhlinzeki wakho wezokwelapha nganoma yiluphi olunye ukwelashwa kwangaphambilini olutholile, ngoba lokhu kudlala indima ebalulekile ekutholeni okulungile kokwelashwa nemithamo yemithi.
Imiphumela emibi ye-peptide receptor radionuclide therapy (PRRT)?
I-Peptide receptor radionuclide therapy (PRRT) uqobo ibekezelela kahle, kepha ngesikhathi sokungenwa yi-amino acid, iziguli zivame ukuba nesicanucanu nokuhlanza (kwesinye isikhathi kubi kakhulu). Lokhu kudinga ukwelashwa okulwa nesicanucanu noma ukwehlisa ijubane lokuphathwa kwe-amino acid. Esikhathini eside, imiphumela emibi izobandakanya ukubalwa kwegazi okuqhubekayo. Sekukonke, le ndlela yokwelashwa ibekezelelwa kahle yiziguli eziningi.
Ukunakekelwa kwasekhaya
Isikhungo sakho sezokwelapha sizokunikeza umhlahlandlela wokwelashwa okulandelayo. Ngoba inani elincane le-radiotherapy lingahlala emzimbeni, iziguli zidinga ukwelashwa okunye ngemuva kwezinsuku eziyi-1-2 ngemuva kokuthola i-peptide receptor radionuclide therapy (PRRT). Ngoba ama-radionuclide asele asuswa emzimbeni ngomchamo nangendle, kubalulekile ukugcina ukuhlanzeka kwendlu yangasese ngalesi sikhathi.
Yiziphi intuthuko entsha ocwaningweni lwe-peptide receptor radionuclide therapy (PRRT)?
Ucwaningo lwe-Peptide receptor radionuclide therapy (PRRT) manje selugxile ekuqedeleni ukuhlolwa komtholampilo kwesigaba sesi-III, futhi luthemba ukuthola imvume ye-US FDA ngezinkomba zayo maduzane ngemva kwalokho. Ucwaningo oluqhubekayo luhlanganisa nocwaningo ngalezi zicelo:
• Sebenzisa ama-peptide amabili ndawonye
• Ama-peptide anemisebe ehlangene nezinye izindlela zokwelapha ngamakhemikhali
• Isicelo se-radiotherapy esiphindaphindiwe
• Ukwandisa inani lezinkomba zalolu hlobo lokwelashwa ngemisebe, okuhlanganisa nezinye izifo ezihlosiwe
• Okunye ukusetshenziswa ngokuhlanganyela kwe-radionuclide-peptide.
